GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-   B6766 CL 316243 disodium saltSummary: murine-selective β3 adrenoceptor agonist B6766 CL 316243 disodium saltSummary: murine-selective β3 adrenoceptor agonist
-   B6536 RS 67506 hydrochlorideSummary: potent and selective 5-HT4 partial agonist B6536 RS 67506 hydrochlorideSummary: potent and selective 5-HT4 partial agonist
-   B6690 RX 821002 hydrochlorideSummary: α2-adrenoceptor antagonist B6690 RX 821002 hydrochlorideSummary: α2-adrenoceptor antagonist
-   B6535 RS 56812 hydrochlorideSummary: 5-HT3 partial agonist B6535 RS 56812 hydrochlorideSummary: 5-HT3 partial agonist
-   B6611 CGP 12177 hydrochlorideSummary: β1/β2-AR antagonist,β3 AR partial agonist B6611 CGP 12177 hydrochlorideSummary: β1/β2-AR antagonist,β3 AR partial agonist
-   B6528 1-Phenylbiguanide hydrochlorideSummary: 5-HT3 receptor agonist B6528 1-Phenylbiguanide hydrochlorideSummary: 5-HT3 receptor agonist
-   B6610 BRL 44408 (maleate)Summary: Selective α2A-AR antagonist B6610 BRL 44408 (maleate)Summary: Selective α2A-AR antagonist
-   B6608 (R)-(-)-Niguldipine hydrochlorideSummary: L-type Ca2+ channel blocker and α1A-adrenoceptor antagonist B6608 (R)-(-)-Niguldipine hydrochlorideSummary: L-type Ca2+ channel blocker and α1A-adrenoceptor antagonist
-   B6513 MK 212 hydrochlorideSummary: 5-HT2C receptor agonist B6513 MK 212 hydrochlorideSummary: 5-HT2C receptor agonist
-   B6479 MDL 11,939Summary: 5-HT2A receptor antagonist B6479 MDL 11,939Summary: 5-HT2A receptor antagonist
